315 related articles for article (PubMed ID: 16913396)
1. Value of pharmaceuticals: ensuring the future of research and development.
Serajuddin HK; Serajuddin AT
J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
[TBL] [Abstract][Full Text] [Related]
2. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
Wolff ME
J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
[TBL] [Abstract][Full Text] [Related]
4. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical research and development and the patent system.
Love J
Int J Health Serv; 2005; 35(2):257-63. PubMed ID: 15932006
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
7. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
Barton JH; Emanuel EJ
JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
[TBL] [Abstract][Full Text] [Related]
8. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
9. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
Tang WL
Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
[TBL] [Abstract][Full Text] [Related]
10. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Cockburn I; Long G
Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
[TBL] [Abstract][Full Text] [Related]
11. Lasofoxifene: CP 336156, CP-336156.
Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
[TBL] [Abstract][Full Text] [Related]
12. The anatomy of medical research: US and international comparisons.
Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
[TBL] [Abstract][Full Text] [Related]
13. Financial aspects and the future of the pharmaceutical industry in the United States of america.
Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
[TBL] [Abstract][Full Text] [Related]
14. Patent reform in the US: what's at stake for pharmaceutical innovation?
Yancey A; Stewart CN
Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
[TBL] [Abstract][Full Text] [Related]
15. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Arnold DG; Troyer JL
J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
[TBL] [Abstract][Full Text] [Related]
16. The shifting functional balance of patents and drug regulation.
Eisenberg RS
Health Aff (Millwood); 2001; 20(5):119-35. PubMed ID: 11558697
[TBL] [Abstract][Full Text] [Related]
17. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
18. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
19. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
20. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
Yamanaka T; Kano S
Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
